Latest filings (excl ownership)
EFFECT
Notice of effectiveness
16 Sep 24
8-K
Departure of Directors or Certain Officers
13 Sep 24
S-3/A
Shelf registration (amended)
12 Sep 24
S-3
Shelf registration
30 Aug 24
EFFECT
Notice of effectiveness
19 Aug 24
424B5
Prospectus supplement for primary offering
16 Aug 24
D
$276.04 k in options / securities to be acquired, sold $276.04 k, 20 investors
16 Aug 24
S-3/A
Shelf registration (amended)
14 Aug 24
8-K
NeuroOne® Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
14 Aug 24
10-Q
2024 Q3
Quarterly report
14 Aug 24
8-K
Entry into a Material Definitive Agreement
7 Aug 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Jul 24
8-K
Material Modifications to Rights of Security Holders
21 Jun 24
S-3
Shelf registration
31 May 24
10-Q
2024 Q2
Quarterly report
14 May 24
8-K
NeuroOne® Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
14 May 24
8-K
NeuroOne® Initiates Limited Commercial Launch of OneRF™ Ablation System
26 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
15 Mar 24
8-K
NeuroOne® Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
13 Feb 24
10-Q
2024 Q1
Quarterly report
13 Feb 24
S-8
Registration of securities for employees
31 Jan 24
ARS
2023 FY
Annual report to shareholders
29 Jan 24
DEF 14A
Definitive proxy
29 Jan 24
424B5
Prospectus supplement for primary offering
5 Jan 24
S-8
Registration of securities for employees
15 Dec 23
10-K
2023 FY
Annual report
15 Dec 23
8-K
NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update
14 Dec 23
8-K
NeuroOne® Receives FDA 510(k) Clearance to Market its OneRF™ Ablation System
11 Dec 23
424B5
Prospectus supplement for primary offering
1 Dec 23
8-K
NeuroOne® Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe
16 Nov 23
8-K
Volker strengthens existing management team in areas of commercialization, business development, and reimbursement
14 Nov 23
8-K
NeuroOne® Provides Progress Update on FDA 510(k) Submission for OneRF™ Ablation System
7 Nov 23
8-K
NeuroOne® Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
14 Aug 23
10-Q
2023 Q3
Quarterly report
14 Aug 23
8-K
NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock
27 Jul 23
424B5
Prospectus supplement for primary offering
26 Jul 23
424B5
Prospectus supplement for primary offering
24 Jul 23
424B5
Prospectus supplement for primary offering
24 Jul 23
10-Q
2023 Q2
Quarterly report
12 May 23
8-K
NeuroOne® Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
11 May 23
Latest ownership filings
4
Steve Mertens
2 Oct 24
4
Mark Christianson
2 Oct 24
4
David A Rosa
2 Oct 24
4
Steve Mertens
4 Sep 24
4
Mark Christianson
4 Sep 24
4
David A Rosa
4 Sep 24
4
PAUL BUCKMAN
5 Aug 24
4
Steve Mertens
2 Aug 24
4
Mark Christianson
2 Aug 24
4
David A Rosa
2 Aug 24
4
Steve Mertens
2 Jul 24
4
David A Rosa
2 Jul 24
4
Mark Christianson
2 Jul 24
4
Mark Christianson
11 Jun 24
4
Mark Christianson
7 Jun 24
4
Steve Mertens
4 Jun 24
4
Mark Christianson
4 Jun 24
4
David A Rosa
4 Jun 24
144
Notice of proposed sale of securities
24 May 24
4
Steve Mertens
2 May 24
4
Mark Christianson
2 May 24
4
David A Rosa
2 May 24
4
Steve Mertens
23 Apr 24
4
Mark Christianson
23 Apr 24
4
David A Rosa
23 Apr 24
4
Steve Mertens
2 Apr 24
4
Mark Christianson
2 Apr 24
4
David A Rosa
2 Apr 24
4
Steve Mertens
4 Mar 24
4
David A Rosa
4 Mar 24
4
Mark Christianson
4 Mar 24
4
Steve Mertens
21 Feb 24
4
Ronald W. McClurg
21 Feb 24
4
Mark Christianson
21 Feb 24
4
David A Rosa
21 Feb 24
SC 13G
Nantahala Capital Management, LLC
14 Feb 24
4
Steve Mertens
1 Feb 24
4
Mark Christianson
1 Feb 24
4
David A Rosa
1 Feb 24
SC 13G
LYTTON LAURENCE W
11 Jan 24